ReviewPharmaceutics2025
Challenges and Innovations in Paediatric Brain Tumour Treatments.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paediatric brain tumours are the most common solid tumours and the leading cause of cancer-related mortality in children. Current treatment, which includes surgery, chemotherapy, and radiotherapy, has improved survival for some types of them but is associated with significant long-term side effects that reduce the quality of life. These unique limitations highlight the urgent need for novel therapeutic strategies tailored to the specific biology and vulnerabilities of the developing brain. This review focuses on clinical trials conducted over the past decade in paediatric brain tumours to elucidate emerging therapeutic directions. By analysing trial phases, type of interventions, and molecular targets, we aimed to identify trends that could inform future treatment development. Our findings show that targeted therapies, particularly kinase inhibitors, epigenetic modulators, and immunotherapies, represent the most frequently explored interventions, although most trials remain in early clinical phases. Diagnostic innovations, including hybrid PET/MRI and molecular profiling, highlight a shift to precision medicine. Collectively, these trends reveal a diversifying therapeutic field that may, with international collaboration and long-term safety evaluation, transform outcomes for children with paediatric brain tumours.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.